



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JANUARY 16, 2013

PTAS

CHANDRA E. EIDT
601 UNION STREET, SUITE 4400
SEATTLE, WA 98101

502196015

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 01/15/2013

REEL/FRAME: 029633/0837
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 236071-1000

ASSIGNOR:

PROGENICS PHARMACEUTICALS, INC.

DOC DATE: 01/08/2013

ASSIGNEE:

CYTODYN, INC.
5 CENTERPOINTE DRIVE, SUITE 400
LAKE OSWEGO, OREGON 97035

APPLICATION NUMBER: 08831823

FILING DATE: 04/02/1997

PATENT NUMBER: 6344545

ISSUE DATE: 02/05/2002

TITLE: METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

APPLICATION NUMBER: 08973601

FILING DATE: 03/16/1998

PATENT NUMBER: 6261763

ISSUE DATE: 07/17/2001

TITLE: FLUORESCENCE RESONANCE ENERGY TRANSFER SCREENING ASSAY FOR THE IDENTIFICATION OF COMPOUNDS THAT ARE CAPABLE OF ABROGATING MACROPHAGE -TOPIC HIV-1 CELL FUSION

APPLICATION NUMBER: 09412284

FILING DATE: 10/05/1999

PATENT NUMBER: 6972126

ISSUE DATE: 12/06/2005

TITLE: MONOCLONAL ANTIBODIES AND METHOD FOR INHIBITING FUSION OF HIV-1 TO CD4+ CELLS

APPLICATION NUMBER: 09460216 FILING DATE: 12/13/1999
 PATENT NUMBER: 7858298 ISSUE DATE: 12/28/2010
 TITLE: METHODS OF INHIBITING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
 (HIV-1) INFECTION THROUGH THE ADMINISTRATION OF CCR5 CHEMOKINE
 RECEPTOR ANTAGONISTS

APPLICATION NUMBER: 09891062 FILING DATE: 06/25/2001
 PATENT NUMBER: 7118859 ISSUE DATE: 10/10/2006
 TITLE: METHODS FOR INHIBITING HIV-1 INFECTION

APPLICATION NUMBER: 09904356 FILING DATE: 07/12/2001
 PATENT NUMBER: 7862994 ISSUE DATE: 01/04/2011
 TITLE: METHODS FOR INHIBITING HIV-1 ENVELOPE GLYCOPROTEIN-MEDIATED
 MEMBRANE FUSION

APPLICATION NUMBER: 09912824 FILING DATE: 07/25/2001
 PATENT NUMBER: 7138119 ISSUE DATE: 11/21/2006
 TITLE: COMPOSITIONS AND METHODS FOR INHIBITION OF HIV-1 INFECTION

APPLICATION NUMBER: 10116797 FILING DATE: 04/05/2002
 PATENT NUMBER: 7060273 ISSUE DATE: 06/13/2006
 TITLE: METHODS FOR INHIBITING HIV-1 INFECTION

APPLICATION NUMBER: 10371483 FILING DATE: 02/21/2003
 PATENT NUMBER: 7122185 ISSUE DATE: 10/17/2006
 TITLE: ANTI-CCR5 ANTIBODY

APPLICATION NUMBER: 11258963 FILING DATE: 10/25/2005
 PATENT NUMBER: 7901685 ISSUE DATE: 03/08/2011
 TITLE: METHODS FOR ASSAYING INHIBITION OF HIV-1 ENVELOPE
 GLYCOPROTEIN-MEDIATED MEMBRANE FUSION

APPLICATION NUMBER: 11520556 FILING DATE: 09/12/2006
 PATENT NUMBER: 7736649 ISSUE DATE: 06/15/2010
 TITLE: METHODS OF INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION
 THROUGH THE ADMINISTRATION OF SYNERGISTIC COMBINATIONS OF
 ANTI-CCR5 MONOCLONAL ANTIBODIES, FUSION INHIBITORS, AND
 CD4-GP120 BINDING INHIBITORS.

APPLICATION NUMBER: 11544346 FILING DATE: 10/05/2006
 PATENT NUMBER: 7345153 ISSUE DATE: 03/18/2008
 TITLE: COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION

APPLICATION NUMBER: 11581944 FILING DATE: 10/16/2006
 PATENT NUMBER: 7851600 ISSUE DATE: 12/14/2010
 TITLE: ANTI-CCR5 ANTIBODY

APPLICATION NUMBER: 11581945 FILING DATE: 10/16/2006
 PATENT NUMBER: 7666419 ISSUE DATE: 02/23/2010
 TITLE: ANTI-CCR5 ANTIBODY

APPLICATION NUMBER: 11894568 FILING DATE: 08/20/2007
 PATENT NUMBER: 7935797 ISSUE DATE: 05/03/2011
 TITLE: CCR5 CHEMOKINE RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES CAPABLE
 OF INHIBITING HIV-1 CELL FUSION

APPLICATION NUMBER: 12452739 FILING DATE: 02/12/2010
 PATENT NUMBER:
 TITLE: METHODS OF INHIBITING INFECTION BY DIVERSE SUBTYPES OF
 DRUG-RESISTANT HIV-1

APPLICATION NUMBER: 12590005 FILING DATE: 10/30/2009
PATENT NUMBER: ISSUE DATE:
TITLE: METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS

APPLICATION NUMBER: 12954464 FILING DATE: 11/24/2010
PATENT NUMBER: ISSUE DATE:
TITLE: METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS

APPLICATION NUMBER: 13093331 FILING DATE:
PATENT NUMBER: ISSUE DATE:
TITLE: METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

APPLICATION NUMBER: 13582243 FILING DATE:
PATENT NUMBER: ISSUE DATE:
TITLE: CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF

APPLICATION NUMBER: 13621590 FILING DATE: 09/17/2012
PATENT NUMBER: ISSUE DATE:
TITLE: METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS

APPLICATION NUMBER: 61339191 FILING DATE: 03/01/2010
PATENT NUMBER: ISSUE DATE:
TITLE: CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF

APPLICATION NUMBER: FILING DATE:
PATENT NUMBER: ISSUE DATE:
PCT NUMBER: US2011026647
TITLE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Progenics Pharmaceuticals, Inc.	01/08/2013

RECEIVING PARTY DATA	
Name:	CytoDyn, Inc.
Street Address:	5 Centerpointe Drive, Suite 400
City:	Lake Oswego
State/Country:	OREGON
Postal Code:	97035

PROPERTY NUMBERS Total: 23	
Property Type	Number
Patent Number:	7122185
Patent Number:	7851600
Patent Number:	7666419
Patent Number:	7138119
Patent Number:	7736649
Patent Number:	7060273
Application Number:	12954464
Patent Number:	6261763
Patent Number:	6972126
Patent Number:	7901685
Patent Number:	7862994
Patent Number:	7118859
Patent Number:	7345153
Patent Number:	6344545
Patent Number:	7858298

CH \$920.00 7122185

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT is made by Progenics Pharmaceuticals, Inc., a Delaware corporation, having an address of 777 Old Saw Mill River Road, Tarrytown, New York 10591, (hereinafter referred to as "ASSIGNOR");

WHEREAS, ASSIGNOR is the applicant/owner of the inventions listed on the attached ANNEX A; and

WHEREAS, CytoDyn, Inc., a Colorado corporation, having an address of 5 Centerpointe Drive, Suite 400, Lake Oswego, Oregon, 97035 (hereinafter referred to as "ASSIGNEE"), is desirous of acquiring the entire right, title and interest in and to the Inventions and designs, to any application for Letters Patent or Patents of the United States, including the Patent Applications, any and all divisional, reissue, continuation, continuation-in-part, substitute, reexamined patents or other applications and/or extensions thereof, and in and to any and all Letters Patent or Patents, United States or foreign, to be obtained therefore and thereon together with all rights and causes of action pertaining thereto (the "Patent Rights"); and

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers unto ASSIGNEE, effective as of the date of the assignment referenced below, the entire right, title and interest in and to the Inventions and to the Patent Rights, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from any application for Letters Patent or Patents, United States or foreign, the same to be held and enjoyed by ASSIGNEE for its own use and benefit, and for ASSIGNEE's legal representatives, successors and assigns, to the full end of the term for which any application for Letters Patent or Patents, United States or foreign, on which the Invention is granted as fully, exclusively and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment not been made.

ASSIGNOR agrees to assist, cooperate and execute all instruments and documents required for the sale, transfer, conveyance, assignment, confirmation and protection of the Inventions by application for Letters Patent or Patents, United States or foreign, for any proceedings regarding applications for Letters Patent or Patents on the Inventions, or for the purpose of protecting title to the Inventions or Letters Patent or Patents therefor as provided in the 16-October-2012 Intellectual Property Assignment Agreement between ASSIGNOR and ASSIGNEE.

IN TESTIMONY WHEREOF, on behalf of ASSIGNOR, an authorized officer has signed his or her name on the date indicated below:

Effective this 8th day of JANUARY, 2013 at TARRYTOWN,
NEW YORK.



Signature


DAVID E. MARTIN
Printed Name

GENERAL COUNSEL
Title

STATE OF NEW YORK)
COUNTY OF WESTCHESTER) ss:
)

On this 8th day of JANUARY, 2013, before me personally appeared
DAVID E. MARTIN, personally known to me (or proved to me on the basis of
satisfactory evidence) to be the person that executed the within and foregoing instrument, and
acknowledged said instrument to be his or her free and voluntary act and deed for the uses and
purposes therein mentioned, and on oath stated that he or she was authorized to execute said
instrument.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal the
day and year first above written.


Signature

ELIZABETH MANOCCHI
Printed Name of Notary

My appointment expires: JULY 16, 2015

ELIZABETH MANOCCHI
Notary Public, State of New York
Qualified in Westchester County
No. 01MA6061645
Commission Expires July 16, 2015

ANNEX A

- 1) U.S. Patent No. 7,122,185, titled "Anti-CCR5 Antibody" which was issued on October 17, 2006, filed on February 21, 2003, and assigned Application Serial No. 10/371,483.

Chain of Title: An assignment from inventors William C. Olson and Paul J. Madden to Progenics Pharmaceuticals, Inc. was recorded on August 18, 2003 at Reel 014393, Frame 0471.

- 2) U.S. Patent No. 7,851,600, titled "Anti-CCR5 Antibody" which was issued on December 14, 2010, filed on October 16, 2006, and assigned Application Serial No. 11/581,944.

Chain of Title: U.S. Patent No. 7,851,600 is a continuation of U.S. Patent No. 7,122,185. An assignment from inventors William C. Olson and Paul J. Madden to Progenics Pharmaceuticals, Inc. was recorded in the parent application on August 18, 2003 at Reel 014393, Frame 0471.

- 3) U.S. Patent No. 7,666,419, titled "Anti-CCR5 Antibody" which was issued on February 23, 2010, filed on October 16, 2006, and assigned Application Serial No. 11/581,945.

Chain of Title: U.S. Patent No. 7,666,419 is a continuation of U.S. Patent No. 7,122,185. An assignment from inventors William C. Olson and Paul J. Madden to Progenics Pharmaceuticals, Inc. was recorded in the parent application on August 18, 2003 at Reel 014393, Frame 0471.

- 4) U.S. Patent No. 7,138,119, titled "Compositions and Methods for Inhibition of HIV-1 Infection" which was issued on November 21, 2006, filed on July 25, 2001, and assigned Application Serial No. 09/912,824.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on January 11, 2002 at Reel 012455, Frame 0713.

- 5) U.S. Patent No. 7,736,649, titled "Methods of Inhibiting Human Immunodeficiency Virus Infection through the Administration of Synergistic Combinations of Anti-CCR5 Monoclonal Antibodies, Fusion Inhibitors, and CD4-GP120 Binding Inhibitors" which was issued on June 15, 2010, on September 12, 2006, and assigned Application Serial No. 11/520,556.

Chain of Title: U.S. Patent No. 7,736,649 is a continuation of U.S. Patent No. 7,138,119. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on January 11, 2002 at Reel 012455, Frame 0713.

- 6) U.S. Patent No. 7,060,273, titled "Methods for Inhibiting HIV-1 Infection" which was issued on June 13, 2006, filed on April 5, 2002, and assigned Application Serial No. 10/116,797.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on October 28, 2002 at Reel 013461, Frame 0107.

7) U.S. Patent Application Serial No. 12/954,464, titled "Methods for Reducing Viral Load in HIV-1 Infected Patients" filed on November 24, 2010.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on September 27, 2011 at Reel 026975, Frame 0384.

8) U.S. Patent No. 6,261,763, titled "Fluorescence Resonance Energy Transfer Screening Assay for the Identification of Compounds that are Capable of Abrogating Macrophage -Tropic HIV-1 Cell Fusion" which was issued on July 17, 2001, filed on March 16, 1998, and assigned Application Serial No. 08/973,601.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on March 16, 1998 at Reel 009079, Frame 0564.

9) U.S. Patent No. 6,972,126, titled "Monoclonal Antibodies and Method for Inhibiting Fusion of HIV-1 to CD4+ Cells" which was issued on December 6, 2005, filed on October 5, 1999, and assigned Application Serial No. 09/412,284.

Chain of Title: U.S. Patent No. 6,972,126 is a continuation of U.S. Patent No. 6,261,763. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on March 16, 1998 at Reel 009079, Frame 0564.

10) U.S. Patent No. 7,901,685, titled "Methods for Assaying Inhibition of HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion" which was issued on March 8, 2011, filed on October 25, 2005, and assigned Application Serial No. 11/258,963.

Chain of Title: U.S. Patent No. 7,901,685 is a continuation of U.S. Patent No. 6,972,126, which itself is a continuation of U.S. Patent No. 6,261,763. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application, U.S. Patent No. 6,261,763, on March 16, 1998 at Reel 009079, Frame 0564.

11) U.S. Patent No. 7,862,994, titled "Methods for Inhibiting HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion" which was issued on January 4, 2011, filed on July 12, 2001, and assigned Application Serial No. 09/904,356.

Chain of Title: U.S. Patent No. 7,862,994 is a continuation of U.S. Patent No. 6,261,763. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on March 16, 1998 at Reel 009079, Frame 0564.

12) U.S. Patent No. 7,118,859, titled "Methods for Inhibiting HIV-1 Infection" which was issued on October 10, 2006, filed on June 25, 2001, and assigned Application Serial No. 09/891,062.

Chain of Title: U.S. Patent No. 7,118,859 is a continuation of U.S. Patent Application Serial No. 09/118,415. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on October 7, 1998 at Reel 9518, Frame 0698.

13) U.S. Patent No. 7,345,153, titled "Compounds Capable of Inhibiting HIV-1 Infection" which was issued on March 18, 2008, filed on October 5, 2006, and assigned Application Serial No. 11/544,346.

Chain of Title: U.S. Patent No. 7,345,153 is a continuation of U.S. Patent No. 7,118,859, which itself is a continuation of U.S. Patent Application Serial No. 09/118,415. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application, U.S. Patent Application Serial No. 09/118,415, on October 7, 1998 at Reel 9518, Frame 0698.

14) U.S. Patent No. 6,344,545, titled "Method for Preventing HIV-1 Infection of CD4+ Cells" which was issued on February 5, 2002, filed on April 2, 1997, and assigned Application Serial No. 08/831,823.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on June 23, 1997 at Reel 008570, Frame 0163.

15) U.S. Patent No. 7,858,298, titled "Methods of Inhibiting Human Immunodeficiency Virus Type 1 (HIV-1) Infection through the Administration of CCR5 Chemokine Receptor Antagonists" which was issued on December 28, 2010, filed on December 13, 1999, and assigned Application Serial No. 09/460,216.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on November 17, 1998 at Reel 009608, Frame 0335.

16) U.S. Patent No. 7,935,797, titled "CCR5 Chemokine Receptor-Specific Monoclonal Antibodies Capable of Inhibiting HIV-1 Cell Fusion" which was issued on May 3, 2011, filed on August 20, 2007, and assigned Application Serial No. 11/894,568.

Chain of Title: U.S. Patent No. 7,935,797 is a continuation of U.S. Patent No. 7,858,298. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on November 17, 1998 at Reel 009608, Frame 0335.

17) U.S. Patent Application Serial No. 13/093,331, titled "Methods for Preventing HIV-1 Infection of CD4+ Cells" filed on April 25, 2011.

Chain of Title: U.S. Patent Application Serial No. 13/093,331 is a divisional of U.S. Patent No. 7,935,797, which itself is a continuation of U.S. Patent No. 7,858,298. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application, U.S. Patent No. 7,858,298, on November 17, 1998 at Reel 009608, Frame 0335.

18) U.S. Provisional Patent Application Serial No. 61/339,191, titled "Concentrated Protein Formulations and Uses Thereof" filed on March 1, 2010.

Chain of Title: An assignment from the inventor to Progenics Pharmaceuticals, Inc. was recorded on February 28, 2011 at Reel 025870, Frame 0852.

19) International Patent Application Serial No. PCT/US2011/026647, titled "Concentrated Protein Formulations and Uses Thereof" filed on March 1, 2011.

Chain of Title: International Patent Application Serial No. PCT/US2011/026647 claims priority to U.S. Provisional Patent Application Serial No. 61/339,191. An assignment from the inventor to Progenics Pharmaceuticals, Inc. was recorded in the provisional parent application on February 28, 2011 at Reel 025870, Frame 0852.

20) U.S. Patent Application Serial No. 13/582,243, titled "Concentrated Protein Formulations and Uses Thereof" which has an international filing date of March 1, 2011.

Chain of Title: U.S. Patent Application Serial No. 13/582,243 claims priority to International Patent Application Serial No. PCT/US2011/026647, which itself claims priority to U.S. Provisional Patent Application Serial No. 61/339,191. An assignment from the inventor to Progenics Pharmaceuticals, Inc. was recorded in the parent provisional application on February 28, 2011 at Reel 025870, Frame 0852.

21) U.S. Patent Application Serial No. 12/590,005, titled "Methods for Reducing Viral Load in HIV-1 Infected Patients" filed on October 30, 2009.

Chain of Title: An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded on June 25, 2010 at Reel 024598, Frame 0994.

22) U.S. Patent Application Serial No. 13/621,590, titled "Methods for Reducing Viral Load in HIV-1 Infected Patients" filed on September 17, 2012.

Chain of Title: U.S. Patent Application Serial No. 13/621,590 is a continuation of U.S. Application Serial No. 12/590,005. An assignment from the inventors to Progenics Pharmaceuticals, Inc. was recorded in the parent application on June 25, 2010 at Reel 024598, Frame 0994.

23) U.S. Patent Application Serial No. 12/452,739, titled "Methods of Inhibiting Infection by Diverse Subtypes of Drug-Resistant HIV-1" which has an international filing date of February 12, 2010.

Chain of Title: An assignment from the inventor to Progenics Pharmaceuticals, Inc. was recorded on February 13, 2010 at Reel 023947, Frame 0491.